15 June, 2026 1:00 CET

MOUNTAIN VIEW, CA. – Endurance Bio Inc. has selected EGeen International, Inc., to support a Phase 2 of T-168, its lead drug candidate, in Parkinson’s disease.
Endurance Bio Inc., a San Francisco Bay Area-based biotechnology company focused on developing treatments for neurodegenerative, metabolic and other indications affecting human health span. Additional information is available on the website of Endurance Bio Inc. at www.endurance-bio.com.
EGeen International, Inc. is leveraging its global drug development expertise combined with cost effective global clinical trial operations to more expeditiously meet the worldwide demand for approved high quality pharmaceutical products.